RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment
Together we are stronger
Handy, C. E., Quispe, R., Pinto, X., Blaha, M. J., Blumenthal, R. S., Michos, E. D., Lima, J. A. C., Guallar, E., Ryu, S., Cho, J., Kaye, J. A., Comin-Colet, J., Corbella, X., & Cainzos-Achirica, M. (2018). Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: Together we are stronger. Circulation, 138(7), 727-734. https://doi.org/10.1161/CIRCULATIONAHA.118.035516
Cardiovascular disease (CVD) and cancer continue to be the 2 leading causes of death in developed countries despite significant improvements in the prevention, screening, and treatment of both diseases. They remain significant public health problems, growing in importance globally. Despite this threat, the fields of cardiology and oncology have been relatively disconnected. With many shared modifiable risk factors, cancer and CVD often coexist in the same individuals; those diagnosed with lung cancer, breast cancer, and colon cancer are at higher risk of CVD, and those with CVD are at higher risk of developing many types of common cancers. Screening paradigms have been established in parallel, but there are opportunities for combined risk assessments for cancer and CVD risk. Joining forces for combined cardiovascular and hemato-oncological preventive and research efforts will likely have synergistic, worldwide public health benefits.